{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T07:17:21Z","timestamp":1781421441426,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.antiviral.2020.104710","type":"journal-article","created":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T09:23:14Z","timestamp":1578820994000},"page":"104710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease"],"prefix":"10.1016","volume":"176","author":[{"given":"Islam T.M.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Bowlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104710_bib1","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","article-title":"Cytomegalovirus infection in transplant recipients","volume":"70","author":"Azevedo","year":"2015","journal-title":"Clinics"},{"key":"10.1016\/j.antiviral.2020.104710_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00006454-200301000-00012","article-title":"A wider role for congenital cytomegalovirus infection in sensorineural hearing loss","volume":"22","author":"Barbi","year":"2003","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.antiviral.2020.104710_bib3","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104710_bib4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/peds.104.1.55","article-title":"Symptomatic congenital cytomegalovirus infection in infants born to mothers with preexisting immunity to cytomegalovirus","volume":"104","author":"Boppana","year":"1999","journal-title":"Pediatrics"},{"key":"10.1016\/j.antiviral.2020.104710_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","article-title":"New therapies for human cytomegalovirus infections","volume":"159","author":"Britt","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104710_bib6","series-title":"Preclinical Pharmacokinetic, Safety Pharmacology and in Vitro and Oral Toxicology of MBX-400, a Potent Inhibitor of Human Cytomegalovirus","author":"Brooks","year":"2013"},{"key":"10.1016\/j.antiviral.2020.104710_bib7","series-title":"Clinical Pharmacokinetics of MBX-400; a Potent Antiviral in Development for CMV and HHV-6","author":"Brooks","year":"2016"},{"key":"10.1016\/j.antiviral.2020.104710_bib8","series-title":"Phase 1A Clinical Trial Results of MBX-400; a Potent Antiviral in Development for CMV and HHV-6","author":"Brooks","year":"2015"},{"key":"10.1016\/j.antiviral.2020.104710_bib9","series-title":"MBX-400, Active against Betaherpesviruses, Does Not Cause Genotoxicity in in Vitro and in Vivo Models","author":"Brooks","year":"2016"},{"key":"10.1016\/j.antiviral.2020.104710_bib10","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/rmv.655","article-title":"Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection","volume":"20","author":"Cannon","year":"2010","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2020.104710_bib11","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1128\/AAC.00449-16","article-title":"Potency and stereoselectivity of cyclopropavir triphosphate action on human cytomegalovirus DNA polymerase","volume":"60","author":"Chen","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib12","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/jm0205245","article-title":"Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus","volume":"46","author":"Chen","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2020.104710_bib13","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/AAC.01259-10","article-title":"Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility","volume":"55","author":"Chou","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1128\/AAC.02544-13","article-title":"Cytomegalovirus mutants resistant to ganciclovir and cidofovir differ in susceptibilities to synguanol and its 6-ether and 6-thioether derivatives","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1128\/AAC.05559-11","article-title":"Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure","volume":"56","author":"Chou","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib16","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/clinids\/13.2.315","article-title":"Infectious diseases society of America and centers for disease control. Summary of a workshop on surveillance for congenital cytomegalovirus disease","volume":"13","author":"Demmler","year":"1991","journal-title":"Rev. Infect. Dis."},{"issue":"Suppl. 4","key":"10.1016\/j.antiviral.2020.104710_bib17","doi-asserted-by":"crossref","first-page":"S182","DOI":"10.1093\/cid\/cit609","article-title":"Congenital cytomegalovirus infection: audiologic outcome","volume":"57","author":"Fowler","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104710_bib18","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.02311-13","article-title":"Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells","volume":"58","author":"Gentry","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bcp.2010.09.005","article-title":"Phosphorylation of antiviral and endogenous nucleotides to di- and triphosphates by guanosine monophosphate kinase","volume":"81","author":"Gentry","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2020.104710_bib20","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1128\/AAC.00468-10","article-title":"Stereoselective phosphorylation of cyclopropavir by pUL 97 and competitive inhibition by maribavir","volume":"54","author":"Gentry","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib21","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"issue":"Suppl. T3","key":"10.1016\/j.antiviral.2020.104710_bib22","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/45.suppl_4.29","article-title":"Betaherpesviruses in transplant recipients","volume":"45","author":"Griffiths","year":"2000","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMe1401567","article-title":"Taming the transplantation troll by targeting terminase","volume":"370","author":"Griffiths","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104710_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.antiviral.2018.09.015","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: orthopox-, adeno-, and herpesviruses","volume":"159","author":"Hartline","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104710_bib25","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1128\/AAC.00571-11","article-title":"Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase","volume":"55","author":"James","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib26","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/pin.12502","article-title":"Pathogenesis of developmental anomalies of the central nervous system induced by congenital cytomegalovirus infection","volume":"67","author":"Kawasaki","year":"2017","journal-title":"Pathol. Int."},{"key":"10.1016\/j.antiviral.2020.104710_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.antiviral.2018.09.016","article-title":"A standardized approach to the evaluation of antivirals against DNA viruses: polyomaviruses and lymphotropic herpesviruses","volume":"159","author":"Keith","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104710_bib28","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1128\/AAC.48.12.4745-4753.2004","article-title":"Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections","volume":"48","author":"Kern","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib29","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.49.3.1039-1045.2005","article-title":"In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication","volume":"49","author":"Kern","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2015.04.001","article-title":"TAOK3 phosphorylates the methylenecyclopropane nucleoside MBX 2168 to its monophosphate","volume":"119","author":"Komazin-Meredith","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2020.104710_bib31","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1128\/AAC.00978-13","article-title":"Human herpesvirus 6 U69 kinase phosphorylates the methylenecyclopropane nucleosides cyclopropavir, MBX 2168, and MBX 1616 to their monophosphates","volume":"57","author":"Komazin-Meredith","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib32","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/AAC.01726-13","article-title":"Human cytomegalovirus UL97 kinase is involved in the mechanism of action of methylenecyclopropane analogs with 6-ether and -thioether substitutions","volume":"58","author":"Komazin-Meredith","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1056\/NEJM199907083410203","article-title":"Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric pulmonary and cardiovascular complications of vertically transmitted HIV infection study group","volume":"341","author":"Kovacs","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104710_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1080\/15257770903172720","article-title":"Synthesis and enantioselectivity of cyclopropavir phosphates for cellular GMP kinase","volume":"28","author":"Li","year":"2009","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.antiviral.2020.104710_bib35","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2020.104710_bib36","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104710_bib37","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104710_bib38","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104710_bib39","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1128\/AAC.00429-13","article-title":"Synthesis and antiviral activities of methylenecyclopropane analogs with 6-alkoxy and 6-alkylthio substitutions that exhibit broad-spectrum antiviral activity against human herpesviruses","volume":"57","author":"Prichard","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib40","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00717-19","article-title":"Phase ib trial to evaluate the safety and pharmacokinetics of multiple ascending doses of filociclovir (MBX-400, cyclopropavir) in healthy volunteers","volume":"63","author":"Rouphael","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib41","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1086\/508173","article-title":"Seroprevalence of cytomegalovirus infection in the United States, 1988-1994","volume":"43","author":"Staras","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104710_bib42","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01301-19","article-title":"Activation of 6-alkoxy-substituted methylenecyclopropane nucleoside analogs requires enzymatic modification by adenosine deaminase-like protein 1","volume":"63","author":"Vollmer","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104710_bib43","series-title":"Advances in Antiviral Drug Design","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1075-8593(06)05003-9","article-title":"Methylenecyclopropane analogues of nucleosides as anti-herpes agents","author":"Zemlicka","year":"2007"},{"key":"10.1016\/j.antiviral.2020.104710_bib44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1021\/jm030316s","article-title":"Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides","volume":"47","author":"Zhou","year":"2004","journal-title":"J. Med. Chem."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422030005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635422030005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:32:13Z","timestamp":1759062733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635422030005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"alternative-id":["S016635422030005X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104710","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The discovery and development of filociclovir for the prevention and treatment of human cytomegalovirus-related disease","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104710"}}